Dominique Berton

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García et al. · The Lancet · 2023 · 175 citations

Oncology, Cervical Cancer, Metronomic Therapy +6

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial

Jean‐Sébastien Frenel, J.W. Kim, Nanda Aryal et al. · Annals of Oncology · 2022 · 140 citations

Post-hoc Analyses, Medicine, Subsequent Chemotherapy +8

Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer

David M. O’Malley, Ana Oaknin, Bradley J. Monk et al. · Gynecologic Oncology · 2021 · 127 citations · Full text

Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors

Thierry André, Dominique Berton, Giuseppe Curigliano et al. · JAMA Network Open · 2023 · 103 citations · Full text

Safety and efficacy of anti–PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.

Thierry André, Dominique Berton, Giuseppe Curigliano et al. · Journal of Clinical Oncology · 2021 · 96 citations

Immunology, Pathology, Immunotherapeutics +19